The abilities to escape apoptosis induced by anticancer drugs are an essential factor of
carcinogenesis and a hallmark of resistance to
cancer therapy. In this study, we identified hTERTR-FAM96A (human
telomerase reverse transcriptase-family with sequence similarity 96 member A) as a new efficient agent for
apoptosome-activating and anti-
tumor protein and investigated the potential
tumor suppressor function in
hepatocellular carcinoma. The hTERTR-FAM96A fusion
protein was constructed by genetic engineering and its anticancer function of hTERTR-FAM96A was explored in vitro and in vivo by investigating the possible preclinical outcomes. Effects of hTERTR-FAM96A on improvement of apoptotic sensitivity and inhibition of migration and invasion were examined in
cancer cells and
tumors. Our results showed that the
therapeutic effects of hTERTR-FAM96A were highly effective for inhibiting
tumor growth and inducing apoptosis of
hepatocellular carcinoma cells in H22-bearing nude mice. The hTERTR-FAM96A fusion
protein could specifically bind with Apaf-1 and hTERT, which further induced apoptosis of
hepatocellular carcinoma cells and improved apoptosis sensitivity. Our results indicated that hTERTR-FAM96A treatment enhanced cytotoxic effects by upregulation of cytotoxic T lymphocyte responses,
interferon-γ release, and T lymphocyte infiltration. In addition, hTERTR-FAM96A led to
tumor-specific immunologic cytotoxicity through increasing apoptotic body on hepatocellular
tumors. Furthermore, hTERTR-FAM96A dramatically inhibited
tumor growth, reduced death rate, and prolonged mice survival in
hepatocellular carcinoma mice derived from three independent
hepatocellular carcinoma mice cohorts compared to control groups. In summary, our data suggest that hTERTR-FAM96A may serve as an efficient anti-
tumor agent for the treatment of
hepatocellular carcinoma.